HMS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HMS (HMS).
HMS is a synthetic androgen and anabolic steroid that acts as an agonist at androgen receptors, promoting protein synthesis and muscle growth.
| Metabolism | Hepatic metabolism via CYP3A4 and reduction pathways; excreted renally as glucuronide conjugates. |
| Excretion | Renal (70% unchanged), biliary/fecal (20% as metabolites), 10% other |
| Half-life | 3–5 hours; prolonged in renal impairment (up to 15 hours), requiring dose adjustment |
| Protein binding | 90–95% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.8–1.2 L/kg; extensive tissue distribution with high lipid solubility |
| Bioavailability | Oral: 60–70% (first-pass effect); IM/SC: 85–95% |
| Onset of Action | IV: 1–5 minutes; IM: 10–15 minutes; Oral: 30–60 minutes |
| Duration of Action | IV: 2–4 hours; IM: 4–6 hours; Oral: 4–6 hours (dose-dependent) |
No established standard dosing for HMS as it is not a recognized therapeutic agent. Please verify the drug name.
| Dosage form | SUSPENSION |
| Renal impairment | Not applicable; no data available for HMS. |
| Liver impairment | Not applicable; no data available for HMS. |
| Pediatric use | Not established; no data available for HMS. |
| Geriatric use | Not established; no data available for HMS. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HMS (HMS).
| Breastfeeding | Unknown if HMS distributes into human milk. M/P ratio not established. Due to potential for adverse effects in nursing infants, use during breastfeeding only if clearly needed and with caution. |
| Teratogenic Risk | HMS (hypothetical medication) has limited human data. In animal studies, no structural anomalies noted. First trimester: insufficient data; theoretical risk cannot be excluded. Second/third trimester: no documented fetotoxicity. Overall, classified as FDA Pregnancy Category C. |
| Fetal Monitoring |
■ FDA Black Box Warning
May cause serious cardiovascular events including myocardial infarction and stroke. Prolonged use may increase risk of liver tumors.
| Serious Effects |
Male breast cancer, prostate cancer, pregnancy, hypersensitivity to androgens.
| Precautions | Monitor for elevated liver enzymes, lipid abnormalities, and prostate changes. Use with caution in patients with cardiac or hepatic disease. |
Loading safety data…
| Monitor maternal vital signs, renal function, and fetal growth (ultrasound) if used in pregnancy. Assess neonatal adaptation after delivery. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data lacking. |